Drug Interactions between interferon gamma-1b and oxtriphylline
This report displays the potential drug interactions for the following 2 drugs:
- interferon gamma-1b
- oxtriphylline
Interactions between your drugs
oxtriphylline interferon gamma-1b
Applies to: oxtriphylline and interferon gamma-1b
MONITOR: The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2. Physiologic events and drugs that induce interferon synthesis (e.g., viral infection, influenza vaccination) have also been reported to decrease metabolism and potentiate the effects of certain drugs including theophylline. Some authorities suggest that the interaction with peginterferon alfa-2a may be maximal after more than 4 weeks of concomitant therapy.
MANAGEMENT: Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.
References
- Kramer P, Tsuru M, Cook CE, et al. "Effect of influenza vaccine on warfarin anticoagulation." Clin Pharmacol Ther 35 (1984): 416-8
- Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part II)." Clin Pharmacokinet 20 (1991): 135-50
- Williams SJ, Baird-Lambert JA, Farrell GC "Inhibition of theophylline metabolism by interferon." Lancet 10/24/87 (1987): 939-41
- Jonkman JH, Nicholson KG, Farrow PR, et al. "Effects of alpha-interferon on theophylline pharmacokinetics and metabolism." Br J Clin Pharmacol 27 (1989): 795-802
- Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K "Depression of drug-metabolizing activity in the human liver by interferon-beta." Hepatology 17 (1993): 65-9
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation PROD (2001):
- Sakai H, Okamoto T, Kikkawa Y "Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid." J Pharmacol Exp Ther 263 (1992): 381-6
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.